4 results
Primary Objective:- To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) and pembrolizumab versus treatment of physician*s choice (TPC) and pembrolizumab. Secondary…
•To compare progression-free survival (PFS) as assessed by blinded independent central review (BICR) between sacituzumab govitecan (SG) versus treatment of physician*s choice (TPC)Secondary Objectives:•To compare overall survival (OS) between the 2…
Our first aim is to evaluate the validity of the developed arm leg ergometer prototype during an incremental exercise test by comparing the outcomes with a regular bicycle ergometer test. The second objective is to describe the movement of…
To compare the overall survival (OS) of sacituzumab govitecan (SG) versus docetaxel.